Cargando…

The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus

INTRODUCTION: ENDURE (ClinicalTrials.gov identifier, NCT00856284), a multicenter, double-blind, active-controlled study of 2639 patients with uncontrolled type 2 diabetes mellitus (T2DM), found that metformin in combination with alogliptin (12.5 and 25 mg doses), when compared to standard add-on the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gordon, Jason, McEwan, Phil, Hurst, Michael, Puelles, Jorge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118244/ https://www.ncbi.nlm.nih.gov/pubmed/27787778 http://dx.doi.org/10.1007/s13300-016-0206-7

Ejemplares similares

Factors Predictive of Weight Gain and Implications for Modeling in Type 2 Diabetes Patients Initiating Metformin and Sulfonylurea Combination Therapy
por: Gordon, Jason P., et al.
Publicado: (2015)

Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
por: Kay, Stephen, et al.
Publicado: (2017)

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
por: Holland, Daniel Q, et al.
Publicado: (2014)

Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective
por: Charokopou, M., et al.
Publicado: (2015)

Diabetes mellitus in the young: Gliptins or sulfonylurea after metformin?
por: Muthukrishnan, J., et al.
Publicado: (2012)

Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy
por: Lorenzoni, Valentina, et al.
Publicado: (2017)

Retrospective Database Analysis Evaluating the Clinical Outcomes of Changing Treatment of People with Type 2 Diabetes Mellitus (T2DM) from Other DPP-4 Inhibitor Therapy to Alogliptin in a Primary Care Setting
por: Strain, W. David, et al.
Publicado: (2019)

Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study
por: Gordon, Jason, et al.
Publicado: (2018)

Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care‐based cohort study, with economic assessment of patient outcomes
por: Gordon, Jason, et al.
Publicado: (2017)

Effects of metformin and alogliptin on body composition in people with type 2 diabetes
por: Takeshita, Yumie, et al.
Publicado: (2018)

Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
por: Kousoulakou, Hara, et al.
Publicado: (2017)

Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea
por: Shin, Yujin, et al.
Publicado: (2020)

Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin
por: Kim, Ye An, et al.
Publicado: (2015)

Starting with low dose sulfonylurea and metformin in early stage type 2 diabetes mellitus
por: George, Joe
Publicado: (2015)

Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors Versus Sulfonylureas as the First Add-On to Metformin Monotherapy: A Retrospective Cohort Study
por: Roberto, Giuseppe, et al.
Publicado: (2022)

Safety of add-on sulfonylurea therapy in patients with type 2 diabetes using metformin: a population-based real-world study
por: Hougen, Ingrid, et al.
Publicado: (2021)

Comparison of Antidiabetic Regimens in Patients with Type 2 Diabetes Uncontrolled by Combination Therapy of Sulfonylurea and Metformin: Results of the MOHAS Disease Registry in Korea
por: Choi, Sung Hee, et al.
Publicado: (2017)

Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis
por: Jeon, Won Kyeong, et al.
Publicado: (2021)

Efficacy of metformin versus sulfonylurea derivative in HNF4A-MODY
por: Oosterom, Nicole, et al.
Publicado: (2022)

Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn’s disease: a systematic review and clinician surveys
por: Gordon, Jason P., et al.
Publicado: (2015)

Review of the Case Reports on Metformin, Sulfonylurea, and Thiazolidinedione Therapies in Type 2 Diabetes Mellitus Patients
por: Susilawati, Elis, et al.
Publicado: (2023)

Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes
por: Kwon, Christina S., et al.
Publicado: (2018)

Correction to: “Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysis”
por: Jeon, Won Kyeong, et al.
Publicado: (2022)

Efficacy and Safety of Alogliptin in Elderly Patients With Type 2 Diabetes Mellitus
por: Takeda, Hiroshi, et al.
Publicado: (2019)

Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus
por: Kaku, Kohei, et al.
Publicado: (2019)

Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)
por: Komajda, Michel, et al.
Publicado: (2008)

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
por: Häring, Hans-Ulrich, et al.
Publicado: (2013)

Comparative effect of metformin versus sulfonylureas with dementia and Parkinson’s disease risk in US patients over 50 with type 2 diabetes mellitus
por: Newby, Danielle, et al.
Publicado: (2022)

The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark
por: Ehlers, Lars H., et al.
Publicado: (2022)

Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post‐hoc analysis of concomitant add‐on versus sequential add‐on to metformin and of triple versus dual therapy with metformin
por: Del Prato, Stefano, et al.
Publicado: (2018)

Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial
por: Xu, Mingtong, et al.
Publicado: (2023)

Hospitalization for Heart Failure Among Patients With Diabetes Mellitus and Reduced Kidney Function Treated With Metformin Versus Sulfonylureas: A Retrospective Cohort Study
por: Richardson, Tadarro L., et al.
Publicado: (2021)

The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus
por: Dudkowski, Caroline, et al.
Publicado: (2016)

What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient
por: Strain, W. David, et al.
Publicado: (2020)

The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy
por: Tai, He, et al.
Publicado: (2016)

Low Branched Chain Amino Acids and Tyrosine in Thai Patients with Type 2 Diabetes Mellitus Treated with Metformin and Metformin-Sulfonylurea Combination Therapies
por: Sriboonvorakul, Natthida, et al.
Publicado: (2021)

Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus
por: Davies, M J, et al.
Publicado: (2012)

Comparison between the Therapeutic Effect of Metformin, Glimepiride and Their Combination as an Add-On Treatment to Insulin Glargine in Uncontrolled Patients with Type 2 Diabetes
por: Park, Cheol-Young, et al.
Publicado: (2014)

Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis
por: Qian, Dan, et al.
Publicado: (2018)

Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients
por: Wang, Fei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_48rrer4kmrv31qfvh8ok3kcfo9